SynthesisCancer medicine2025
Exploration of the Optimal Treatment Modality for Vitreoretinal Lymphoma: A PRISMA Compliant Meta-Analysis and Systematic Review.
Synthesis in Cancer medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Exploration of the Optimal Treatment Modality for Vitreoretinal Lymphoma: A PRISMA Compliant Meta-Analysis and Systematic Review.Cancer medicine · 2025Pooled it
- Review
- Systemic high-dose MTX and BTK inhibitors in vitreoretinal lymphoma: efficacy and survival analysis.Blood science (Baltimore, Md.) · 2026Article
- Case Report: Longitudinal analysis of local immunoregulatory mediators in a DLBCL vitreoretinal lymphoma receiving local chemotherapy.Frontiers in medicine · 2026Article
- Recent advances in the diagnosis and treatment of refractory ocular inflammatory diseases: focus on uveitic macular edema, acute retinal necrosis, and vitreoretinal lymphoma.Japanese journal of ophthalmology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundVitreoretinal lymphoma (VRL) is regarded as a subtype of primary central nervous system lymphoma (PCNSL). Hence, extending progression-free survival (PFS) is crucial for enhancing the prognosis of VRL patients. Nevertheless, a lack of standard treatment options currently exists for VRL. This systematic review aims to explore the most optimal treatment strategy.
methodsThe methods for this systematic review and meta-analysis adhered to PRISMA guidelines and followed a protocol registered on the PROSPERO registry. A search was conducted on PubMed, Embase, and Scopus up to October 14, 2023, using predefined search terms. Primary endpoints included overall response rate (ORR) and complete response rate (CRR), while secondary endpoints comprised overall survival (OS) and progression-free survival (PFS).
resultsThirty-seven studies comprising 801 patients were included in the meta-analysis. The pooled CRR was 85%, and the ORR was 93%. The pooled 1-year PFS was 83%, and the 2-year PFS was 58%. The 1-year OS was 92%, and the 2-year OS was 80%. The combined median PFS was 22.87 months, and the median OS was 51.19 months. Survival analysis of the extracted data showed significant associations between PFS and OS with systemic therapy (p = 0.00098 and p = 0.0091) and multi-strategy combination therapy (p = 0.0081 and p = 0.007); however, age, gender, and bilateral involvement exhibited no significant relationship (p > 0.05).
conclusionsIn conclusion, while existing treatment strategies have led to higher remission rates and longer OS for VRL patients, PFS remains suboptimal. The primary focus of future clinical and basic research will be to explore effective treatment strategies for controlling disease recurrence or progression.
trial registrationThis meta-analysis was registered in the international prospective register of systematic reviews (PROSPERO) (CRD42023400305).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.